Vyv Announces Groundbreaking Inactivation And Killing Of Viruses With Its UV-free Antimicrobial Light Technology

What Kind of Equipment is Used to Analyze DNA?

Below are some of a few basic processes followed throughout DNA testing. The general procedure entails:  • Isolating DNA from a sample containing the needed...

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

Vyv, a female-founded and led health-tech industry leader and pioneer of antimicrobial LED technology, announces the recent independent test results confirming efficacy of its antimicrobial light technology (405nm) for killing* viruses.

Numerous studies have proven the effectiveness of Vyv’s visible light against bacteria, mold, fungi, and yeast.

This recent study has confirmed, through an independent third-party lab, Vyv’s antimicrobial LED products are also effective against non-enveloped viruses, which are the most difficult class of virus to kill*.

“The implications of this are vast because, unlike harmful UV-C light, Vyv’s patented technology can be used continuously and without restriction 24/7 around people, animals, and plants. The recent findings of enhanced efficacy against viruses greatly expand the antimicrobial impact delivered to spaces currently protected with Vyv technology, as well as in new spaces,” said Vyv CEO and co-founder Colleen Costello. “With our overhead LED products, Vyv is already lighting offices, schools and school buses, athletic centers, factories and hospitals. We’re also embedding the same technology in many challenging spaces, including behind elevator buttons, inside consumer products such as humidifiers and bathroom fans, and in airplanes, trains, and public buses.”

Additionally, a recent separate third-party study completed by the Icahn School of Medicine at Mount Sinai also demonstrated efficacy results using ranges of light in the 400-420nm range on inactivating enveloped viruses. With Vyv’s commitment to ongoing research and development advancements of a myriad of new products for healthier spaces, the company will continue to expand its virus testing in the coming months.

The company has announced several high-profile business partnerships and investments with industry front-runners over the past six months. While the COVID-19 global pandemic continues to impact day-to-day life around the world, Vyv has joined forces and expanded development projects with Middleby Corporation, Citi, NJ Transit, Delta Air Lines, Broan-NuTone, Dorel Juvenile and Brilli, among several other well-respected brands. Most recently, Vyv announced a partnership with the Healthcare Association of New York State (HANYS), which is working to advance new approaches to infection control and prevention by dosing interior environments continuously with antimicrobial light to stop and kill* viruses, bacteria, fungi, mold and other organisms.

“Our partners have long understood the threats to global health and wellness. Many of these companies began engineering new solutions with Vyv’s antimicrobial light long before the current pandemic. We’ve been on a path together to bring a new class of continuous microbial protection to address the world’s ever-evolving microbial challenges,” said Costello.

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles